Niagen Bioscience, Inc. (NAGE)
| Market Cap | 527.50M |
| Revenue (ttm) | 99.60M |
| Net Income (ttm) | 8.55M |
| Shares Out | 77.92M |
| EPS (ttm) | 0.11 |
| PE Ratio | 61.55 |
| Forward PE | 58.03 |
| Dividend | n/a |
| Ex-Dividend Date | n/a |
| Volume | 684,491 |
| Open | 7.33 |
| Previous Close | 7.39 |
| Day's Range | 6.76 - 7.33 |
| 52-Week Range | 2.31 - 9.18 |
| Beta | 2.21 |
| Analysts | n/a |
| Price Target | n/a |
| Earnings Date | Mar 4, 2025 |
About NAGE
Niagen Bioscience, Inc. operates as a bioscience company engages in developing healthy aging products. The company operates through three segments: Consumer products; Ingredients; and Analytical Reference Standards and Services. It provides finished dietary supplement products that contain its proprietary ingredients directly to consumers and distributors; nicotinamide adenine dinucleotide (NAD+) test kits to healthcare practitioners; and develops and commercializes proprietary-based ingredient technologies, including food-grade, Niagen, and ph... [Read more]
Financial Performance
Financial StatementsNews
Niagen Bioscience Secures U.S. Patent for the Composition of Matter for Nicotinamide Riboside (NR) Salt Forms
LOS ANGELES--(BUSINESS WIRE)---- $NAGE #IP--Niagen Bioscience, Inc. (NASDAQ: NAGE) (formerly ChromaDex Corp.), the global authority on NAD+ (nicotinamide adenine dinucleotide) with a focus on the scie...
ChromaDex Evolves Into Niagen Bioscience, Marking a New Era of Uncovering the Potential of NAD+ With Precision Science
LOS ANGELES--(BUSINESS WIRE)---- $NAGE #Bioscience--Niagen Bioscience, Inc. (Nasdaq: NAGE) (formerly ChromaDex Corp.), the global authority on NAD+ (nicotinamide adenine dinucleotide) with a focus on ...
ChromaDex Corp. Announces Name Change to Niagen Bioscience, Inc. and New Ticker Symbol "NAGE" Effective March 19, 2025
LOS ANGELES--(BUSINESS WIRE)---- $CDXC #InvestorRelations--ChromaDex Corp. (NASDAQ:CDXC), the global authority on NAD+ (nicotinamide adenine dinucleotide) with a focus on the science of healthy aging,...
ChromaDex to Present at the 37th Annual Roth Conference
LOS ANGELES--(BUSINESS WIRE)---- $CDXC #ChromaDex--ChromaDex Corp. (NASDAQ: CDXC), the global authority on nicotinamide adenine dinucleotide (NAD+) with a focus on the science of healthy aging, today ...
ChromaDex Capitalizes On Longevity Boom But Valuation Remains High
ChromaDex Corporation shows strong revenue growth and profitability, driven by its NAD+ precursors and flagship product Niagen, despite high valuation and execution risks. Record-breaking financial pe...
ChromaDex Corporation (CDXC) Q4 2024 Earnings Call Transcript
ChromaDex Corporation (NASDAQ:CDXC) Q4 2024 Earnings Conference Call March 4, 2025 4:30 PM ET Company Participants Ben Shamsian - Vice President, Lytham Partners, Investor Relations Rob Fried - Chief...
ChromaDex Corporation Reports Fourth Quarter and Fiscal Year 2024 Results
LOS ANGELES--(BUSINESS WIRE)---- $CDXC #ChromaDex--ChromaDex Corp. (NASDAQ:CDXC) today announced fourth quarter and fiscal year 2024 financial results. Fourth Quarter 2024 Total net sales of $29.1 mil...
ChromaDex to Report Fourth Quarter and Fiscal Year 2024 Financial Results on Tuesday, March 4, 2025
LOS ANGELES--(BUSINESS WIRE)---- $CDXC #2024Earnings--ChromaDex Corp. (NASDAQ:CDXC), the global authority on nicotinamide adenine dinucleotide (NAD+) research with a focus on healthy aging, announces ...
ChromaDex to Participate in the Lytham Partners 2025 Investor Healthcare Summit on January 13, 2025
LOS ANGELES--(BUSINESS WIRE)---- $CDXC #ChromaDex--ChromaDex Corp. (NASDAQ: CDXC), the global authority on nicotinamide adenine dinucleotide (NAD+) with a focus on the science of healthy aging, today ...
ChromaDex Named to the Inc. 2024 Best in Business List in the Health Products Category
LOS ANGELES--(BUSINESS WIRE)---- $CDXC #ChromaDex--ChromaDex Corp. (NASDAQ:CDXC) proudly announces its inclusion on the Inc. 2024 Best in Business list in the Health Products category. Inc.'s annual B...
ChromaDex's Patented Nicotinamide Riboside (NR) Ingredient, Niagen®, Featured as the Hero Ingredient in Longevity.Technology's Inaugural Longevity Supplement
LOS ANGELES--(BUSINESS WIRE)---- $CDXC #ChromaDex--ChromaDex Corp. (NASDAQ: CDXC), the global authority on nicotinamide adenine dinucleotide (NAD+) with a focus on the science of healthy aging, announ...
ChromaDex's Pharmaceutical-Grade Niagen® IV Now Accessible at over 200 Restore Hyper Wellness Clinics Nationwide
LOS ANGELES--(BUSINESS WIRE)---- $CDXC #ChromaDex--ChromaDex Corp. (NASDAQ:CDXC), the global authority on nicotinamide adenine dinucleotide (NAD+) research with a focus on healthy aging, today announc...
ChromaDex Corporation (CDXC) Q3 2024 Earnings Call Transcript
ChromaDex Corporation (NASDAQ:CDXC) Q3 2024 Earnings Conference Call October 31, 2024 4:30 PM ET Company Participants Ben Shamsian - IR Rob Fried - CEO Ozan Pamir - CFO Andrew Shao - SVP, Scientific ...
ChromaDex Corporation Reports Third Quarter 2024 Financial Results
LOS ANGELES--(BUSINESS WIRE)---- $CDXC #ChromaDex--ChromaDex Corp. (NASDAQ:CDXC) today announced financial results for the third quarter of 2024. Third Quarter 2024 Financial and Recent Operational Hi...
ChromaDex to Report Third Quarter 2024 Financial Results on Thursday, October 31, 2024
LOS ANGELES--(BUSINESS WIRE)---- $CDXC #ChromaDex--ChromaDex Corp. (NASDAQ: CDXC), the global authority on nicotinamide adenine dinucleotide (NAD+) research with a focus on healthy aging, announced th...
ChromaDex to Participate in the 17th Annual LD Micro Main Event
LOS ANGELES--(BUSINESS WIRE)---- $CDXC #ChromaDex--ChromaDex Corp. (NASDAQ:CDXC), the global authority on nicotinamide adenine dinucleotide (NAD+) research with a focus on healthy aging, announced tha...
Yasmeen Nkrumah-Elie, Ph.D., Global Director of External Research at ChromaDex, Honored with the Trailblazing Woman Award by Radicle Science and Council for Responsible Nutrition (CRN)
LOS ANGELES--(BUSINESS WIRE)---- $CDXC #CRN--ChromaDex Corp. (NASDAQ:CDXC), the global authority on nicotinamide adenine dinucleotide (NAD+) research with a focus on healthy aging, announced today tha...
ChromaDex to Participate in a Fireside Chat at the Lytham Partners Fall 2024 Investor Conference
LOS ANGELES--(BUSINESS WIRE)---- $CDXC #ChromaDex--ChromaDex Corp. (NASDAQ:CDXC), the global authority on nicotinamide adenine dinucleotide (NAD+) with a focus on healthy-aging research, today announc...
ChromaDex Appoints Ozan Pamir as Chief Financial Officer
LOS ANGELES--(BUSINESS WIRE)---- $CDXC #CFO--ChromaDex Corp. (NASDAQ:CDXC), the global authority on nicotinamide adenine dinucleotide (NAD+) research with a focus on healthy aging, announces the appoi...
ChromaDex Announces Expansion of Pharmaceutical-Grade Niagen® IV and Injection Offerings to Additional Leading Wellness Clinics
LOS ANGELES--(BUSINESS WIRE)---- $CDXC #ChromaDex--ChromaDex Corp. (NASDAQ:CDXC), the global authority on nicotinamide adenine dinucleotide (NAD+) research with a focus on healthy aging, is excited to...
ChromaDex Celebrates 25 Years of Innovation and Pioneering NAD+ Research for Healthy Aging Solutions
LOS ANGELES--(BUSINESS WIRE)---- $CDXC #25thAnniversary--ChromaDex Corp. (NASDAQ:CDXC), the global authority on nicotinamide adenine dinucleotide (NAD+) research with a focus on healthy aging, proudly...
ChromaDex to Participate in Renmark's Virtual Non-Deal Roadshow Series On Thursday, August 29, 2024
LOS ANGELES--(BUSINESS WIRE)---- $CDXC #BioScience--ChromaDex Corp. (NASDAQ:CDXC), the global authority on nicotinamide adenine dinucleotide (NAD+) research with a focus on healthy aging, announced to...
ChromaDex Secures U.S. Patent for the Composition of Matter of Salt Forms of NMNH (Dihydronicotinamide Mononucleotide), a Precursor to NAD+
LOS ANGELES--(BUSINESS WIRE)---- $CDXC #CellularHealth--ChromaDex Corp. (NASDAQ:CDXC), the global authority on nicotinamide adenine dinucleotide (NAD+) research with a focus on healthy aging, today an...
ChromaDex Corporation Reports Second Quarter 2024 Financial Results
LOS ANGELES--(BUSINESS WIRE)---- $CDXC #Bioscience--ChromaDex Corp. (NASDAQ:CDXC) today announced financial results for the second quarter of 2024. Second Quarter 2024 Financial and Recent Operational...
ChromaDex to Present at Canaccord Genuity's 44th Annual Growth Conference
LOS ANGELES--(BUSINESS WIRE)---- $CDXC #BioScience--ChromaDex Corp. (NASDAQ:CDXC), the global authority on nicotinamide adenine dinucleotide (NAD+) research with a focus on healthy aging, today announ...